Dechra Veterinary Products is to launch a medication for treating canine hypoadrenocorticism at BSAVA Congress.
Zycortal is the only European licensed treatment for the condition.
Hypoadrenocorticism, also known as Addison’s disease, is caused by a reduction in corticosteroid secretion from the adrenal glands.
Symptoms can include:
- lack of appetite
- tremors or shaking
- muscle weakness
- low body temperature
- low heart rate
If left untreated, Addison’s disease can present as an acute, life-threatening emergency.
Zycortal is a prolonged release suspension used as replacement therapy for mineralocorticoid deficiency in dogs with Addison’s disease.
It has proven effective in clinical trials, with more than 80% of dogs responding positively to treatment.
The drug contains desoxycortone pivalate, which is said to control serum electrolytes more effectively than fludrocortisone, the human treatment prescribed for dogs with Addison’s disease, and is considered the preferential drug for mineralocorticoid supplementation.
BSAVA Congress delegates will be able to find out more about Zycortal at Dechra’s stand (500) and discuss the benefits of the treatment.
For more information, visit www.dechra.co.uk